Nov 11, 2019 / 10:00AM GMT
Heikki Lanckriet - Expedeon AG - CEO, Chief Scientific Officer & Member of Management Board
Thank you very much and welcome, everybody, to today's call. Some very exciting news this morning, and this call is really to provide some more context to the transaction that we've announced this morning and to also give you some insights on where we see the future of the business and where we see the opportunities for Expedeon AG.
So first things first. We always start with our usual disclaimer. So I'll let you have a few seconds to read this, and then we'll move on to the order of the day.
So first of all, Expedeon. I'll give you a brief overview of what Expedeon has been and what we've built over the past 3 years as an organization. We'll then provide a little bit more context to the proposed transaction and the rationale of this transaction. And then finally, we'll close with some remarks on the new organization and where we see the future.
So in terms of the business as it is today. Our commercial focus -- we're essentially a tools and reagents organization, and our focus has
Abcam PLC Abcam to Acquire Expedeon's Proteomics and Immunology Business - M&A Call Transcript
Mar 01, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers